Bria-IMT Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer July 15, 2025
Data from Ongoing Dose Escalation of BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma presented July 8, 2025
Austrian Regulatory Green Light Enables ADC Combination Testing and Ph 1 Site Expansion for ES2B-C001 July 8, 2025
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders July 1, 2025
Preliminary data announced for gedatolisib from Ph 1 CELC-G-201 trial in metastatic CRPC and Ph 2 HER2+ metastatic breast cancer patients July 1, 2025
Results from Ph 1/2 Study of Sacituzumab Tirumotecan (sac-TMT) in Solid Tumors Refractory to Standard Therapies Published in Journal of Hematology & Oncology June 17, 2025
FDA authorizes Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers June 17, 2025
NDA submitted to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer June 11, 2025
Ph 1/2 trial of AVZO-023 initiated in patients with advanced or metastatic HR+/HER2- breast cancer and select other advanced solid tumors June 10, 2025
CHMP recommends EU approval of Itovebi for PIK3CA-mutated, ER+ve, HER2-neg, advanced breast cancer May 27, 2025
Trodelvy Demonstrates Significant PFS Improvement in 1L Metastatic TNBC Patients Not Candidates for Checkpoint Inhibitors in ASCENT-03 trial May 27, 2025
Atossa Announced Strategic Decision to Pursue Metastatic Breast Cancer Indication for (Z)-endoxifen May 21, 2025
Ten-year APHINITY data show Perjeta-based regimen reduced the risk of death by 17% in people with HER2+ve early-stage breast cancer May 21, 2025
Two Ph 2 trials of Samuraciclib + SERDs in HR+ve Advanced Breast Cancer demonstrate extended PFS in patients without TP53 mutations or without liver mets May 21, 2025
Enhertu followed by THP before surgery showed statistically significant pCR improvement high-risk HER2-positive early-stage breast cancer patients in DESTINY-Breast11 Ph 3 trial May 13, 2025
First Patient Dosed in STARt-002 Trial of Invikafusp Alfa in Combination with Trodelvy® in Metastatic Breast Cancer May 13, 2025
IND application submitted to the U.S. FDA for UTRxM1-18 for targeting c-MYC driven cancers May 13, 2025
CHMP recommends EU label update for Phesgo to allow administration outside of clinical settings May 6, 2025
